MANGOCEUTICALS, INC. (MGRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 300K 600K 900K Q4 '23: 731.5K Q1 '24: 844.9K Q2 '24: 866.8K Q3 '24: 755K Q4 '24: 615.9K Q1 '25: 511.1K Q2 '25: 516K Q3 '25: 466.9K Q4 '25: 456K Q1 '26: 414.6K Q2 '26: 315.2K Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

0 200K 400K 600K Q4 '23: 431.5K Q1 '24: 521.7K Q2 '24: 504.4K Q3 '24: 442.4K Q4 '24: 380K Q1 '25: 294.6K Q2 '25: 314.8K Q3 '25: 283K Q4 '25: 250.4K Q1 '26: 217.3K Q2 '26: 171.6K Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income TTM

-21M -14M -7M 0 7M 14M 21M Q4 '22: -2M Q1 '23: -4.6M Q2 '23: -6.5M Q3 '23: -7.3M Q4 '23: -9.2M Q1 '24: -9M Q2 '24: -8.9M Q3 '24: -8.9M Q4 '24: -8M Q1 '25: -10.2M Q2 '25: -13.3M Q3 '25: -19.1M Q4 '25: -17.8M Q1 '26: -16.3M Q2 '26: -12.1M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Net Income TTM

-24M -16M -8M 0 8M 16M 24M Q4 '22: -2M Q1 '23: -4.5M Q2 '23: -6.5M Q3 '23: -7.3M Q4 '23: -9.2M Q1 '24: -9M Q2 '24: -9.1M Q3 '24: -9.3M Q4 '24: -8.7M Q1 '25: -11.2M Q2 '25: -14.2M Q3 '25: -19.8M Q4 '25: -20.6M Q1 '26: -19.2M Q2 '26: -15.1M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Cost of Revenue TTM

0 60K 120K 180K Q4 '23: 154.9K Q1 '24: 151.9K Q2 '24: 156K Q3 '24: 125.3K Q4 '24: 93.3K Q1 '25: 97.2K Q2 '25: 86.4K Q3 '25: 67.2K Q4 '25: 54.4K Q1 '26: 37.9K Q2 '26: 29.5K Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q4 '22: -1.3M Q1 '23: -3.1M Q2 '23: -4.8M Q3 '23: -5.9M Q4 '23: -7M Q1 '24: -6.2M Q2 '24: -6M Q3 '24: -5.4M Q4 '24: -4.9M Q1 '25: -6.1M Q2 '25: -5.8M Q3 '25: -5.9M Q4 '25: -5.9M Q1 '26: -4.9M Q2 '26: -3.9M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Free Cash Flow TTM

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '23: -6M Q4 '23: -7M Q3 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q1 '22: 8M Q2 '22: 9M Q3 '22: 10M Q1 '23: 11.3M Q2 '23: 15.8M Q3 '23: 1.1M Q1 '24: 1.6M Q2 '24: 1.7M Q3 '24: 2M Q1 '25: 4.6M Q2 '25: 10M Q3 '25: 11.5M Q1 '26: 16.5M Q2 '26: 17.1M Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '22: -0.20 Q1 '23: -0.43 Q2 '23: -0.53 Q3 '23: -2.13 Q4 '23: -3.97 Q1 '24: -5.24 Q2 '24: -6.47 Q3 '24: -5.91 Q4 '24: -4.53 Q1 '25: -4.15 Q2 '25: -3.35 Q3 '25: -2.90 Q4 '25: -2.39 Q1 '26: -1.49 Q2 '26: -1.01 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.